<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5008323</article-id><article-id pub-id-type="pmid">26943576</article-id><article-id pub-id-type="publisher-id">7846</article-id><article-id pub-id-type="doi">10.18632/oncotarget.7846</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>D'Artista</surname><given-names>Luana</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bisso</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Piontini</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Doni</surname><given-names>Mirko</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Verrecchia</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kress</surname><given-names>Theresia R.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Morelli</surname><given-names>Marco J.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Del Sal</surname><given-names>Giannino</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Amati</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Campaner</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia (IIT), Milan, Italy</aff><aff id="A2"><sup>2</sup> Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, Italy</aff><aff id="A3"><sup>3</sup> Laboratorio Nazionale CIB (LNCIB), Area Science Park, Trieste, Italy</aff><aff id="A4"><sup>4</sup> Dipartimento di Scienze della Vita, Universit&#x000e0; degli Studi di Trieste, Trieste, Italy</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Bruno Amati,</italic><email>bruno.amati@iit.it</email></corresp><corresp id="cor2"><italic>Stefano Campaner,</italic><email>stefano.campaner@iit.it</email></corresp></author-notes><pub-date pub-type="collection"><day>19</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>2</day><month>3</month><year>2016</year></pub-date><volume>7</volume><issue>16</issue><fpage>21786</fpage><lpage>21798</lpage><history><date date-type="received"><day>17</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 D'Artista et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>The c-<italic>myc</italic> proto-oncogene is activated by translocation in Burkitt's lymphoma and substitutions in codon 58 stabilize the Myc protein or augment its oncogenic potential. In wild-type Myc, phosphorylation of Ser 62 and Thr 58 provides a landing pad for the peptidyl prolyl-isomerase Pin1, which in turn promotes Ser 62 dephosphorylation and Myc degradation. However, the role of Pin1 in Myc-induced lymphomagenesis remains unknown. We show here that genetic ablation of <italic>Pin1</italic> reduces lymphomagenesis in E&#x003bc;-<italic>myc</italic> transgenic mice. In both <italic>Pin1</italic>-deficient B-cells and MEFs, the proliferative response to oncogenic Myc was selectively impaired, with no alterations in Myc-induced apoptosis or mitogen-induced cell cycle entry. This proliferative defect wasn't attributable to alterations in either Ser 62 phosphorylation or Myc-regulated transcription, but instead relied on the activity of the ARF-p53 pathway. Pin1 silencing in lymphomas retarded disease progression in mice, making Pin1 an attractive therapeutic target in Myc-driven tumors.</p></abstract><kwd-group><kwd>c-myc</kwd><kwd>Pin1</kwd><kwd>lymphoma</kwd><kwd>proliferation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Pin1 is a Peptidyl-prolyl isomerase (PPIase) of the parvulin-like family that catalyzes the cis/trans isomerization of Prolines in peptide chains [<xref rid="R1" ref-type="bibr">1</xref>]. Among PPIases, Pin1 shows unique specificity, in that it specifically recognizes Prolines followed by a phosphorylated Ser or Thr residue [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. Proline-directed phosphorylation sites are frequent in the cellular proteome and are the targets of several kinases families, including Cyclin-dependent kinases, MAP-kinases, Polo-like kinases, Glycogen Synthase Kinase-3 and p38 kinases. Consistent with such high level of complexity, Pin1 has profound impact on a variety of fundamental biological processes [<xref rid="R4" ref-type="bibr">4</xref>].</p><p>A well-characterized Pin1 substrate is the Myc transcription factor. Pin1 is involved in an intricate phosphorylation/de-phosphorylation cycle that regulates Myc turnover. This regulatory cycle is ignited by ERK mediated phosphorylation of Ser 62, which enables GSK-3b dependent phosphorylation of Thr 58 [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>]. The double phosphorylated form of Myc is bound by Pin1, which allows subsequent de-phosphorylation of Ser 62 and ubiquitin dependent proteasomal degradation of Myc [<xref rid="R7" ref-type="bibr">7</xref>]. Consistent with this model, mutations in Thr 58 stabilize Myc [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R8" ref-type="bibr">8</xref>].</p><p>Myc is an oncogenic factor that is generally over-expressed in tumors: this can happen either indirectly through the activation of oncogenic pathways that stabilize Myc and/or augment c-<italic>myc</italic> transcription, or directly through amplification or translocation of c-<italic>myc</italic> gene, such as in Burkitt' s lymphoma (BL). Most remarkably, in BL, the open-reading frame of the translocated c-<italic>myc</italic> allele is frequently the target of secondary missense mutations [<xref rid="R9" ref-type="bibr">9</xref>]. Adoptive gene transfer experiments in the mouse hematopoietic system directly demonstrated that mutations at codon 58 (one of the hotspots in BL) augment the oncogenic potential of c-<italic>myc</italic> [<xref rid="R10" ref-type="bibr">10</xref>]. On this basis, one might hypothesize that, like Thr 58 mutation, a decrease in Pin1 activity should potentiate the oncogenic action of Myc: this putative tumor suppressive effect of Pin1 might be further reinforced by its positive action on p53 [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R15" ref-type="bibr">15</xref>], a key suppressor of Myc-induced lymphomagenesis [<xref rid="R16" ref-type="bibr">16</xref>].</p><p>The above notwithstanding, other effects of Pin1 would lead one to predict a positive role for this enzyme in Myc-induced lymphomagenesis. In particular, the direct action of Pin1 on Myc may positively modulate its transcriptional activity, either by favoring its interaction with co-activators such as p300 [<xref rid="R17" ref-type="bibr">17</xref>], or by augmenting its dynamic turnover on target genes [<xref rid="R18" ref-type="bibr">18</xref>]. Pin1 may also indirectly favor Myc activity, for example by promoting the degradation of Fbw7 [<xref rid="R19" ref-type="bibr">19</xref>], a ubiquitin ligase that contributes to Myc turnover [<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref>].</p><p>Using mouse genetics, we show that Pin1 is critical for efficient Myc-induced lymphomagenesis. This, however, cannot be accounted for by any of the aforementioned mechanisms. Instead, we report that Pin1 is required to avert the onset of an Arf-p53 dependent cytostatic response following Myc activation. Finally, based on a reverse-genetics approach, we provide proof-of-principle experiments validating Pin1 as a therapeutic target in Myc-driven lymphoma.</p></sec><sec id="s2"><title>RESULTS</title><p>To address the role of Pin1 in Myc-induced lymphomagenesis, we bred <italic>Pin1</italic> knockout mice [<xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R23" ref-type="bibr">23</xref>] with E&#x003bc;-<italic>myc</italic> transgenic mice [<xref rid="R24" ref-type="bibr">24</xref>]. E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic> and E&#x003bc;-<italic>myc Pin1<sup>+/&#x02212;</sup></italic> mice developed lymphomas with similar latency (average onset: 108 days) and penetrance (86% and 92% respectively). E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice, instead, showed enhanced latency (431 days) and reduced penetrance (52%) (Figure <xref ref-type="fig" rid="F1">1A</xref>). This did not merely follow from a primary defect in B cell development, as <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice showed normal formation of bone marrow common myeloid/lymphoid progenitors (B220<sup>&#x02212;</sup>IgM<sup>&#x02212;</sup>CD25<sup>&#x02212;</sup>c-kit<sup>+</sup>) and differentiation to Pro B (B220<sup>+</sup>IgM<sup>&#x02212;</sup>CD25<sup>&#x02212;</sup>c-kit<sup>+</sup>), Pre B (B220<sup>+</sup>IgM<sup>&#x02212;</sup>CD25<sup>+</sup>c-kit<sup>&#x02212;</sup>) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1A</xref>) and immature B cells (B220<sup>+</sup>IgM<sup>+</sup>) (Figure <xref ref-type="fig" rid="F1">1B</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1B-1D</xref>). Hence, loss of Pin1 limits Myc-induced lymphomagenesis.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Lymphomagenesis and pre-tumoral analysis of E&#x003bc;-<italic>myc Pin1&#x02212;/&#x02212;</italic> mice</title><p><bold>A.</bold> Lymphoma-free survival in cohorts of E&#x003bc;-<italic>myc</italic> or control mice of the indicated Pin1 genotypes. The Median survival was 108 days for E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic> (N=30), 431 days for E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> (N=23), and 108 days for E&#x003bc;-<italic>myc Pin1<sup>+/&#x02212;</sup></italic> (N=13). P-values were calculated with the log-rank (Mantel-Cox) test: P = 0.001 for E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> vs. E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic>; P = 0.002 for E&#x003bc;-<italic>myc Pin1</italic>
<sup>&#x02212;/&#x02212;</sup> vs. E&#x003bc;-<italic>myc Pin1<sup>+/&#x02212;</sup></italic>; P = 0.7287 for E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic> vs. E&#x003bc;-<italic>myc Pin1<sup>+/&#x02212;</sup></italic>. No lymphomas arose in non-transgenic mice, regardless of their <italic>Pin1</italic> genotype. In B-F, six weeks old E&#x003bc;-<italic>myc</italic> pre-tumoral mice and age matched non-transgenic mice were analyzed. <bold>B.</bold> Flow cytometric analysis of circulating B cell populations. Pro/Pre B lymphocytes are defined as B220<sup>+</sup>IgM<sup>&#x02212;</sup>, Immature B lymphocytes as B220<sup>+</sup>IgM<sup>+</sup> cells. <bold>C.</bold> Numbers of circulating lymphocytes in the peripheral blood of mice of the indicated genotypes, determined with a Hematological analyzer (Beckman Coulter). <bold>D.</bold> Percentage of apoptotic cells among splenic B220<sup>+</sup> lymphocytes of the indicated genotypes, as assessed by Tunel assay. <bold>E.</bold> Sections of the indicated genotypes were stained with the proliferation marker Ki67. 3-4 mice of each genotype were analyzed. Representative sections are shown. Scale bars: 100 &#x003bc;m. <bold>F.</bold> Cell cycle distribution of circulating B cells, analyzed as described in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1E</xref>. <bold>G.</bold> Viability of splenic B cells purified from healthy E&#x003bc;<italic>-myc</italic> or non-transgenic mice, cultured in the absence of cytokines. After 8 and 20 hours, cells were stained with Propidium Iodide (PI) to exclude dead cells. The percentage of viable PI negative cells, measured by flow cytometry is reported. <bold>H.</bold> Cell cycle entry and proliferation of purified B cells cultured <italic>in vitro</italic> in the presence of LPS, as assessed by continuous labeling with BrdU. In B-D, F, average values and standard deviations are reported, based on the numbers of samples indicated in above the bars. P-values were calculated using Student's t-test.</p></caption><graphic xlink:href="oncotarget-07-21786-g001"/></fig><p>At the pre-tumoral stage, E&#x003bc;-<italic>myc</italic> mice display a characteristic increase in circulating Pro/Pre B cells and a concomitant reduction in immature B cells (Figure <xref ref-type="fig" rid="F1">1B</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1B</xref>) [<xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>]: while this differentiation block was still present in young E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice, these animals showed significantly lower accumulation of Pro/Pre B cells (Figure <xref ref-type="fig" rid="F1">1B</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1B</xref>) and, as a consequence, decreased expansion of total circulating B cells (Figure <xref ref-type="fig" rid="F1">1C</xref>). Reduced expansion of the Pro/Pre B cell compartment was also observed in the bone marrow and in the spleen of E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1C, 1D</xref>). Another feature of the pre-tumoral stage in E&#x003bc;-<italic>myc</italic> mice is the co-occurrence of Myc-induced apoptosis and proliferation [<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R27" ref-type="bibr">27</xref>]: these effects were dissociated in E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> animals, which displayed normal induction of apoptosis (Figure <xref ref-type="fig" rid="F1">1D</xref>), but a defective proliferative response (Figure <xref ref-type="fig" rid="F1">1E, 1F</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1E</xref>). Culturing of control and pre-tumoral E&#x003bc;-<italic>myc</italic> B cells <italic>ex vivo</italic> confirmed that the apoptotic activity of Myc was preserved in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background (Figure <xref ref-type="fig" rid="F1">1G</xref>). In contrast with the proliferative defect of E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> B cells <italic>in vivo</italic>, primary lymphocytes isolated from non-transgenic <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> or <italic>Pin1<sup>+/+</sup></italic> mice entered the cell cycle and proliferated with comparable efficiencies following stimulation with LPS <italic>ex vivo</italic> (Figure <xref ref-type="fig" rid="F1">1H</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1F</xref>), showing that <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> B cells have no intrinsic proliferative defect.</p><p>The effect of Pin1 deletion observed <italic>in vivo</italic> in B cells was corroborated in mouse embryo fibroblasts (MEFs) expressing a 4-hydroxy-tamoxifen (OHT)-inducible MycER chimera: here, continuous MycER activation in proliferating cells preferentially suppressed the growth of <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> relative to <italic>Pin1<sup>+/+</sup></italic> populations, while inducing apoptosis to similar extents with either genotype (Figure <xref ref-type="fig" rid="F2">2A, 2B</xref>). Of note, <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> MEFs proliferated less than wild-type, reflecting the pleiotropic role of Pin1 in regulating cell cycle progression [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R4" ref-type="bibr">4</xref>]. When serum-starved and subsequently induced to enter the cell cycle by treatment with either serum or OHT, <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Pin1<sup>+/+</sup></italic> MEFs entered S-phase with similar efficiencies and kinetics (Figure <xref ref-type="fig" rid="F2">2C, 2D</xref>), showing that Pin1 was dispensable for re-entry into the cell cycle under the control of either endogenous or exogenous Myc [<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R29" ref-type="bibr">29</xref>], and hence for the mitogenic activity of Myc <italic>per se</italic>. Altogether, the above data indicate a specific requirement of Pin1 for sustained proliferation following oncogenic activation of Myc in either B cells or fibroblasts.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Pin1 is required for Myc driven proliferation in MEFs</title><p><bold>A.</bold> Growth of MycER-expressing MEFs [<xref rid="R54" ref-type="bibr">54</xref>] cultured in the presence or absence of OHT. Each curve represent independent low passage MEFs isolates of the indicated genotypes. (AU) arbitrary units. Although population doublings were already reduced upon OHT treatment in wild-type MEFs due to Myc-induced apoptosis, sustained MycER activation markedly reduced the expansion of <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> cultures [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R30" ref-type="bibr">30</xref>]. <bold>B.</bold> Apoptosis in MycER-expressing MEFs assessed by Caspase 3/7 activity. In A., B. data represent the average of a triplicate measure expressed as arbitrary units (AU). <bold>C.</bold> Serum-starved MycER-expressing MEFs cells were stimulated with either 20% serum or OHT, as indicated. After 16 hours MEFs were pulse-labeled with BrdU for 20 min. The percentage of BrdU-positive cells was determined by FACS. <bold>D.</bold> Cell cycle entry and proliferation of MEFs upon serum release, as assessed by continuous labeling with BrdU. In C., D. values represent the average from two independent samples.</p></caption><graphic xlink:href="oncotarget-07-21786-g002"/></fig><p>The proliferative defect of <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> cells was reminiscent of previous observations on Cdk2, deletion of which caused Myc-overexpressing cells to undergo cellular senescence [<xref rid="R30" ref-type="bibr">30</xref>]. Since Cdk2 phosphorylation sites are also Pin1 consensus sites [<xref rid="R31" ref-type="bibr">31</xref>], we hypothesized that Cdk2- and Pin1-nullizygosity may cause similar defects in response to oncogenic Myc. However, unlike what was observed in E&#x003bc;-<italic>myc Cdk2<sup>&#x02212;/&#x02212;</sup></italic> B cells [<xref rid="R30" ref-type="bibr">30</xref>], the mRNAs encoding the Cdk inhibitors p16<sup>INK4a</sup> and p21<sup>Cip1</sup> were not significantly up-regulated in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2A</xref>) and these proteins remained below detection in all samples (data not shown). As expected [<xref rid="R16" ref-type="bibr">16</xref>], the p19<sup>ARF</sup> mRNA and protein accumulated in E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic> B cells accompanied by increased p53 levels, effects that were reduced in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2A, 2B</xref>). Consistent with these results, the quiescent state of E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> B cells was not associated with enhanced expression of a panel of p53 target genes (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2C</xref>). Unlike in E&#x003bc;-<italic>myc Cdk2</italic><sup>&#x02212;/&#x02212;</sup> B cells [<xref rid="R30" ref-type="bibr">30</xref>], we were unable to detect accumulation of Senescence-associated &#x00394;-Galactosidase (SA-&#x00394;-gal) activity in E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> cells (data not shown). Reactive oxygen species (ROS), the DNA damage response (DDR) marker &#x003b3;H2AX and phosphorylation of p53 on Ser 15 are stress-associated features that have also been linked with cellular senescence [<xref rid="R32" ref-type="bibr">32</xref>]. Consistent with previous reports [<xref rid="R33" ref-type="bibr">33</xref>&#x02013;<xref rid="R35" ref-type="bibr">35</xref>] all of these features were elevated in pre-tumoral B cells relative to non-transgenic controls, but were not affected by the Pin1 genotype (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2D, 2E</xref>). Finally, senescence may also follow from telomere dysfunction [<xref rid="R36" ref-type="bibr">36</xref>], and loss of Pin1 has been associated with telomere shortening and premature aging in mice [<xref rid="R37" ref-type="bibr">37</xref>]: however, no significant telomere shortening occurred in mouse B cells upon either Myc expression, Pin1 loss, or both together (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2F</xref>). Altogether, our data lend no support for a mechanistic link between senescence and the proliferative defect of E&#x003bc;<italic>-myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> B cells.</p><p>Survey of Myc mRNA and protein levels in pre-tumoral E&#x003bc;-<italic>myc</italic> B cells revealed a substantially lower accumulation in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> mutant background (Figure <xref ref-type="fig" rid="F3">3A, 3B</xref>). Yet, Myc was clearly active in E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> cells, as apoptosis and blockade of B cell differentiation were induced as efficiently as in control E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic> cells (Figure <xref ref-type="fig" rid="F1">1B, 1D, 1G</xref>): given that induction of apoptosis requires higher Myc levels than the proliferative response [<xref rid="R38" ref-type="bibr">38</xref>], the phenotype of E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> B cells was unlikely to follow merely from an overall decrease in Myc activity. At odds with pre-tumoral samples, the absence of Pin1 did not affect c-<italic>myc</italic> mRNA and Myc protein levels in E&#x003bc;-<italic>myc</italic> tumors (Figure <xref ref-type="fig" rid="F3">3A, 3C</xref>). We conclude that decreased c-<italic>myc</italic> expression most likely followed from the proliferative arrest of pre-tumoral B cells, which tumors had bypassed.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Loss of Pin1 does not affect Myc protein stability in B cells and MEFs</title><p><bold>A.</bold> c-<italic>myc</italic> mRNA levels normalized to the TBP mRNA (TATA Box Binding Protein) in control, pre-tumoral splenic B cells and E&#x003bc;-<italic>myc</italic> tumors of the reported Pin1 genotype, as assessed by RT-qPCR. <bold>B.</bold> Immunoblot analysis of total (Myc), Ser 62-phosphorylated Myc (S62P-Myc) and Thr 58-phosphorylated Myc (T58P-Myc) in B220+ cells purified from spleens of the indicated genotype. Vinculin is shown as loading control. Relative densitometric analysis was performed using the Image Lab 5.0 software. The levels of total Myc normalized to Vinculin, and of S62P-Myc and T58P-Myc normalized to total Myc are reported on the right. In A., B. P-values were calculated using Student's t-test. <bold>C.</bold> Immunoblot analysis of total Myc and S62P-Myc in E&#x003bc;-<italic>myc</italic> tumors of the reported Pin1 genotype. <bold>D.</bold> Immunoblot analysis of endogenous Myc in quiescent MEFs (0h) or the same cells stimulated with 20% serum for the indicated times. Relative quantifications, performed as described in B, are reported at the bottom, for either total Myc (left) or S62P-Myc (right). <bold>E.</bold> Stability of endogenous Myc in asynchronous proliferating <italic>Pin1<sup>+/+</sup></italic> and <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> MEFs. Lysates were prepared at the indicated times after treatment of the cells with cycloheximide (CHX) and immunoblotted for total Myc and vinculin. The quantifications of the immunoblot and calculated Myc half-lives are shown at the bottom. Two independent MEF populations of each genotype were analyzed. One representative experiment is shown.</p></caption><graphic xlink:href="oncotarget-07-21786-g003"/></fig><p>Since Pin1 can favor Ser 62 dephosphorylation and Myc degradation [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R39" ref-type="bibr">39</xref>], its loss would be expected to lead to Myc accumulation, with a relative enrichment of the phospho-Ser 62 (S62P) form. However, the ratios of S62P to total Myc were independent of the Pin1 genotype in either E&#x003bc;-<italic>myc</italic> B cells or MEFs (Figure <xref ref-type="fig" rid="F3">3B-3D</xref>). Accordingly, T58P to total Myc also showed no significant alteration (Figure <xref ref-type="fig" rid="F3">3B</xref>). Total and S62P Myc also accumulated with comparable kinetics following mitogenic stimulation in <italic>Pin1<sup>+/+</sup></italic> and <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> MEFs (Figure <xref ref-type="fig" rid="F3">3D</xref>), and the protein showed similar decay rates upon translational blockade with cycloheximide (CHX) (Figure <xref ref-type="fig" rid="F3">3E</xref>). Altogether, the phenotypes of <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> cells reported here were not directly linked to a deregulation of Myc protein phosphorylation and stability.</p><p>Pin1 may also modulate Myc's transcriptional activity [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. To address this issue, we generated RNA-seq profiles from control and pre-tumoral B cells of either <italic>Pin1</italic> genotype. Unsupervised hierarchical clustering led to the grouping of all non-transgenic samples with no distinction of <italic>Pin1</italic> genotype, implying that Pin1 does not regulate basal transcription in B cells (Figure <xref ref-type="fig" rid="F4">4A</xref>). E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic> and E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> samples formed distinct groups, the latter clustering closer to non-transgenic cells. Consistent with this scenario, gene activation and repression detected in E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic> pre-tumoral relative to <italic>Pin1<sup>+/+</sup></italic> control B cells [<xref rid="R40" ref-type="bibr">40</xref>] were generally reduced in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background (Figure <xref ref-type="fig" rid="F4">4B</xref>). Digital quantification of 754 mRNAs with NanoString technology confirmed this general dampening in their up- or down-regulation, independently from Myc binding to the corresponding promoters [<xref rid="R40" ref-type="bibr">40</xref>] (Figure <xref ref-type="fig" rid="F4">4C</xref>). We further examined a set of 80 genes that were Myc-bound and strongly induced in E&#x003bc;<italic>-myc</italic> B cells [<xref rid="R40" ref-type="bibr">40</xref>]: as above, induction of these genes was reduced - albeit still detectable - in pre-tumoral <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> B cells, but was fully restored in <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> lymphomas (Figure <xref ref-type="fig" rid="F4">4D, 4E</xref>), indicating that Pin1 was not required for Myc transcriptional activity <italic>per se</italic>. This issue was addressed further in MEFs, with a set of 64 MycER-induced or -repressed mRNAs [<xref rid="R40" ref-type="bibr">40</xref>] revealing comparable responses in <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Pin1<sup>+/+</sup></italic> MEFs (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3A</xref>). Moreover, a group of 116 Myc-Dependent Serum Response (MDSR) genes [<xref rid="R29" ref-type="bibr">29</xref>] also showed unaltered responses to serum stimulation in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3B</xref>). Consistent with this result, loss of Pin1 did not suppress binding of Myc to the <italic>Ncl</italic> promoter shortly after serum stimulation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3C</xref>) [<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R41" ref-type="bibr">41</xref>]. Altogether, our data show that Pin1 exerts no essential role in Myc-dependent transcription. We infer that the impaired gene regulation seen in pre-tumoral E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> B cells - including reduced expression of the E&#x003bc;-<italic>myc</italic> transgene itself - most likely follows from their quiescent state. In line with this interpretation, two cyclin-coding (<italic>Ccnb1</italic> and <italic>Ccnd1</italic>) and 28 other cell cycle-associated genes showed lower expression in E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> relative to E&#x003bc;-<italic>myc Pin1<sup>+/+</sup></italic>B cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3D, 3E</xref>). In E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> lymphomas, instead, expression of these genes was back to the levels observed in the <italic>Pin1<sup>+/+</sup></italic> counterparts (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3E</xref>).</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Gene-expression profiling in E&#x003bc;-<italic>myc Pin1&#x02212;/&#x02212;</italic> B cells</title><p>Total RNA from control and pre-tumoral E&#x003bc;-<italic>myc</italic> B cells of the indicated <italic>Pin1</italic> genotypes was profiled by RNA-seq. <bold>A.</bold> Unsupervised hierarchical clustering of the sequenced samples. <bold>B.</bold> Fold-change values (log2FC) for differentially expressed genes (DEGs) in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> relative to the <italic>Pin1<sup>+/+</sup></italic> background. The DEGs shown here were first defined based on their deregulation in E&#x003bc;-<italic>myc</italic> B relative to control B cells in the <italic>Pin1</italic>+/+ background (see Methods). <bold>C.</bold> 754 genes covering the whole expression range and regulatory patterns in E&#x003bc;-<italic>myc</italic> B cells [<xref rid="R40" ref-type="bibr">40</xref>] were analyzed by NanoString and reported as in B. The data are based on the average of 3 biological replicates for each genotype. 361 genes previously classified as Myc-bound in pre-tumoral B cells [<xref rid="R40" ref-type="bibr">40</xref>] are represented in red, and 393 unbound genes in black. <bold>D., E.</bold> NanoString analysis of 80 genes that are amongst the most strongly induced in pre-tumoral B cells and are all bound by Myc in their promoter regions [<xref rid="R40" ref-type="bibr">40</xref>]: D. and E. show the fold-changes in pre-tumoral B cells and lymphomas, respectively, both relative to control B cells. The green lines in B., C., D. represent the linear regression of the data.</p></caption><graphic xlink:href="oncotarget-07-21786-g004"/></fig><p>The ARF/p53 pathway is an important sensor of Myc activation, and is required for tumor suppression in Myc-induced lymphomas [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R27" ref-type="bibr">27</xref>]. Stabilization and activation of p53 by genotoxic stress involves phosphorylation of Ser-Pro motifs and enhanced interaction with Pin1, and <italic>Pin1 null</italic> MEFs are defective in DNA Damage-induced G2 arrest [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>]. Based on these observations, one might have expected impaired p53 activity and accelerated lymphomagenesis in E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice, instead of the observed delay (Figure <xref ref-type="fig" rid="F1">1A</xref>). To address whether this delay was ARF- or p53-dependent, we bred E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice into either of the p53<italic><sup>+/&#x02212;</sup></italic> or <italic>ARF<sup>+/&#x02212;</sup></italic> backgrounds, both known to dramatically accelerate Myc-induced lymphomagenesis with loss of the remaining p53 or ARF allele [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R42" ref-type="bibr">42</xref>]. Most importantly, these effects were still observed in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background, while the delay in lymphomagenesis relative to <italic>Pin1<sup>+/+</sup></italic> counterparts was lost (Figure <xref ref-type="fig" rid="F5">5A-5D</xref>). Inactivation of the ARF-p53 pathway may occur spontaneously during lymphomagenesis in E&#x003bc;-<italic>myc</italic> mice and, as assayed by immunoblot analysis, also occurred in E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 4A</xref>). Hence, the selective pressure against the ARF/p53 pathway was intact in the absence of Pin1 and, once having lost p53 activity, lymphomas were no longer delayed by the lack of Pin1. In an analogous manner, following knockdown of p53, MycER activation no longer slowed proliferation of <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> MEFs (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 4B</xref>). Altogether, our data show that, Pin1 is required to prevent the build-up of an ARF/p53-dependent cytostatic response upon oncogenic activation of Myc.</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Delayed lymphomagenesis in the <italic>Pin1&#x02212;/&#x02212;</italic> background requires Arf/p53 activity</title><p><bold>A.</bold> Lymphoma-free survival in cohorts of E&#x003bc;-<italic>myc</italic> or control mice of the indicated Pin1 and p53 genotypes. The median survival was 39 days for E&#x003bc;-<italic>myc Pin1<sup>+/+</sup><italic>p53</italic><sup>+/&#x02212;</sup></italic> and 42 days for E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup><italic>p53</italic><sup>+/&#x02212;</sup></italic> mice (P=0.5959, Log-Rank, Mantel-Cox). Numbers within brackets indicate sizes of each cohort. <bold>B.</bold> Lymphomas arising in E&#x003bc;-<italic>mycp53<sup>+/&#x02212;</sup></italic> mice show p53 loss of heterozygosis (LOH) in either <italic>Pin1<sup>+/+</sup></italic> or <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background, as shown by RT-PCR. One example of each is shown. Three E&#x003bc;-<italic>myc p53<sup>+/&#x02212;</sup><italic>Pin1</italic><sup>&#x02212;/&#x02212;</sup></italic> tumors were analyzed with the same outcome. <bold>C.</bold> Same as A. with the indicated <italic>Pin1</italic> and <italic>ARF</italic> genotypes. Calculated Median survival was 79 days for E&#x003bc;-<italic>myc Pin1<sup>+/+</sup><italic>ARF</italic><sup>+/&#x02212;</sup></italic> and 95 days for E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup><italic>ARF</italic><sup>+/&#x02212;</sup></italic> mice (P=0.0959, Log-Rank, Mantel-Cox). Note that in both A. and C., E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice with functional p53 and Arf show delayed lymphomagenesis relative to their <italic>Pin1<sup>+/+</sup></italic> counterparts, validating the results shown in Figure <xref ref-type="fig" rid="F1">1A</xref>. <bold>D.</bold> Lymphomas arising <italic>in</italic> E&#x003bc;-<italic>mycPin1<sup>&#x02212;/&#x02212;</sup>ARF<sup>+/&#x02212;</sup></italic> mice show ARF loss of heterozygosis (LOH). Three tumors and one tail from E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup><italic>ARF</italic><sup>+/&#x02212;</sup></italic> mice were analyzed by RT-PCR. <bold>E.</bold> Growth curves of E&#x003bc;-<italic>myc</italic> p53ER<sup>TAMki/&#x02212;</sup> lymphomas overexpressing the anti-apoptotic protein Bcl2. Cells were cultured either in the presence (100 nM) or absence (Mock) of OHT. Cell growth was assessed with the Cell Titer Glo assay. <bold>F.</bold> Cell cycle analysis of Bcl2-expressing E&#x003bc;-<italic>myc</italic> p53ER<sup>TAMki/&#x02212;</sup> lymphomas 48 hours after OHT administration.</p></caption><graphic xlink:href="oncotarget-07-21786-g005"/></fig><p>To further assess how Pin1 influences p53 activity in lymphomas, we used tumors derived from E&#x003bc;-<italic>myc</italic> mice expressing p53ER<sup>TAM</sup>, a latent, OHT-inducible form of p53: as expected [<xref rid="R43" ref-type="bibr">43</xref>], OHT treatment induced an acute apoptotic response in those tumors, which was not affected by loss of Pin1 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 4C</xref>). Over-expression of the anti-apoptotic protein Bcl2 caused a switch in the response to p53ER<sup>TAM</sup> activation, with cells undergoing immediate cell cycle arrest: most importantly, this was also independent from the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background (Figure <xref ref-type="fig" rid="F5">5E, 5F</xref>). Hence, Pin1 had no direct impact on either the apoptotic, or the growth inhibitory activity of p53 in these B cell lymphomas.</p><p>We next asked whether Pin1 would be required for the growth of established lymphomas. To this end, we used an shRNA (shPin1) inserted in a retroviral vector allowing to conditionally silence Pin1 in a doxycycline-dependent manner (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 5A</xref>). Despite a basal leakiness of the shPin1 construct, causing a reduction in Pin1 levels relative to a control shRNA (shRen), administration of doxycycline further reduced Pin1 expression (Figure <xref ref-type="fig" rid="F6">6A, 6B</xref>), reducing cell proliferation <italic>in vitro</italic> in two independent E&#x003bc;-<italic>myc</italic> lymphomas (Figure <xref ref-type="fig" rid="F6">6C</xref>). This was not due to toxicity of doxycycline at the concentrations used, as the antibiotic had no significant effect on shRen-infected cells. To address the role of Pin1 in tumor dissemination <italic>in-vivo</italic>, recipient mice were orthotopically transplanted with an E&#x003bc;-<italic>myc</italic> lymphoma infected with either shRen or shPin1. While a doxycycline diet did not have any effect on the expansion of <italic>in-vivo</italic> growth of the lymphomas infected with shRen, the expansion of shPin1-infected tumors was markedly delayed, significantly improving survival of the animals (Figure <xref ref-type="fig" rid="F6">6D</xref>). A similar effect occurred upon silencing of Pin1 in already established lymphomas (Figure <xref ref-type="fig" rid="F6">6E</xref>). In both instances, those shPin1 lymphomas that ultimately arose in doxycycline-fed animals showed a remarkably low percentage of GFP positive cells (Figure <xref ref-type="fig" rid="F6">6F</xref>): as GFP and the shRNA are expressed from the same precursor RNA (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 5A</xref>), this result demonstrates selective outgrowth of lymphoma cells that escaped Pin1 silencing. Thus, down-regulation of Pin1 in tumors leads to a strong impairment in cancer cell dissemination and maintenance.</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>Pin1 silencing impairs tumor growth and dissemination</title><p><bold>A.</bold> RT-qPCR of Pin1 mRNA. <bold>B.</bold> Immunoblot analysis of Pin1 protein levels, respectively, in a primary E&#x003bc;-<italic>myc</italic> lymphoma infected with conditional shRNAs targeting either Pin1 (shPin1) or renilla luciferase (shRen). The shRNAs were induced by supplementing cells with 1 &#x003bc;g/mL doxycycline for 24 hours. The mRNA data represent the averages &#x000b1;s.d. of three technical replicates, all normalized to the housekeeper TBP and to the mock-treated shRen lymphoma. Vinculin was used as a loading control. <bold>C.</bold> Growth of two independent primary lymphoma populations (Ly27 and Ly28) infected with either shRen or shPin1, and cultured with (dox) or without (mock) doxycycline. <bold>D., E.</bold> Tumor-free survival in mice transplanted with an shRen or shPin1-bearing lymphoma (Ly28). Doxycycline was administered either continuously from the time of transplantation (D.) or following detection of tumor masses, 18 days after transplantation (E.). <bold>F.</bold> Dot plot showing the residual percentage of GFP-positive B220<sup>+</sup> tumor cells detected in the tumor-infiltrated lymph nodes of animals transplanted with shPin1 or shRen lymphomas. Red bars indicate the average values. As in D., E., Mice were fed with doxycycline starting from days 0 or 18, as indicated. GFP serves as a marker for the doxycycline-dependent induction of the shRNAs. * p=0.014; ** p=0.0022; *** p=0.0026 (Log-rank, mantle-cox); <bold><sup>#</sup></bold> p=0.002, <bold><sup>##</sup></bold> p=0.003 (t-test).</p></caption><graphic xlink:href="oncotarget-07-21786-g006"/></fig></sec><sec id="s3"><title>DISCUSSION</title><p>To date, the genetic interaction between Myc and Pin1 was addressed only in a mouse model of mammary carcinogenesis, in which Pin1 was dispensable for Myc-induced tumorigenesis [<xref rid="R44" ref-type="bibr">44</xref>]. Here, we have shown that Pin1 has a critical role in Myc-driven B cell lymphomagenesis in the E&#x003bc;-<italic>myc</italic> transgenic model, in line with its tumor-promoting activity in other cell types and in the context of Ras signaling [<xref rid="R45" ref-type="bibr">45</xref>, <xref rid="R46" ref-type="bibr">46</xref>]. This effect of Pin1 was not due to its known effects on Myc and p53 activities [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R39" ref-type="bibr">39</xref>], which were not directly altered in the <italic>Pin1</italic><sup>&#x02212;/&#x02212;</sup> background.</p><p>Based on previous evidence, the absence of Pin1 should have caused defective de-phosphorylation of Myc Serine 62, a consequent increase in the Ser 62/Thr 58/ phosphorylation ratio, and stabilization of the protein [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R39" ref-type="bibr">39</xref>]. Surprisingly, however, neither B-cells nor MEFs showed clear evidence for an alteration of these features in the <italic>Pin1 <sup>&#x02212;/&#x02212;</sup></italic> background. Two experimental features are noteworthy here: first, the experiments that established the Ser 62/Thr 58/ phosphorylation cycle were based on Myc overexpression with an Adenoviral vector in serum-stimulated fibroblasts [<xref rid="R7" ref-type="bibr">7</xref>], but no data conclusively addressed the role of Pin1 in phosphorylation of the endogenous Myc protein, as done here in <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> fibroblasts and B cells. Second no data were available concerning the identity of the Ub-ligase responsible for Myc degradation following Ser 62 de-phosphorylation [<xref rid="R7" ref-type="bibr">7</xref>]: based on independent work [<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref>], this is commonly surmised to be the T58P-dependent ligase Fbw7 [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R47" ref-type="bibr">47</xref>]. However, the original data on Fbw7 indicated that this enzyme may associate with Thr58-phosphorylated Myc independently from Ser 62 dephosphorylation [<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref>]. It remains to be addressed whether redundant effects exist that compensate for the loss of Pin1 in our experiments. Other data indicated that Pin1 might be critical for the transcriptional activity of Myc [<xref rid="R17" ref-type="bibr">17</xref>]: once again, however, our analysis failed to unravel any defect in Myc-dependent transcription in the <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> background, in either B cells or MEFs. We are thus facing a complex regulatory circuitry, in which deletion of a component - here Pin1 - may not have obvious consequences.</p><p>In line with the preserved transcriptional activity of Myc in <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> cells, Pin1 was required for neither the mitogenic, nor the pro-apoptotic activities of Myc. Upon oncogenic activation of Myc, however, Pin1 was required to prevent the build-up of an ARF/p53-dependent cytostatic response, observable both in <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> MEFs and E&#x003bc;-<italic>myc Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice. Albeit strongly reminiscent of oncogene-induced senescence [<xref rid="R36" ref-type="bibr">36</xref>], which can become limiting for Myc-induced lymphomagenesis in certain genetic backgrounds [<xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R49" ref-type="bibr">49</xref>], this effect lacked any of the canonical features associated with senescent cells. The direct targets of either Myc or Pin1 required to exert this effect remain to be characterized, albeit both regulate genes and proteins involved in a diversity of fundamental biological processes, such as transcription, mRNA stability, cell division, growth, differentiation, stress responses, aging and survival [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R50" ref-type="bibr">50</xref>], many of which may participate to the effects reported here.</p><p>Finally, in line with our data in <italic>Pin1<sup>&#x02212;/&#x02212;</sup></italic> mice, knockdown of Pin1 in E&#x003bc;-<italic>myc</italic> lymphomas impaired their proliferations <italic>in vitro</italic> and significantly enhanced survival of disease-bearing mice. A most interesting implication from these data is that pharmacological inhibition of Pin1 might lead to the proliferative arrest - and possibly elimination - of Myc-driven lymphomas: initial experiments with the Pin1 inhibitory compound PiB [<xref rid="R51" ref-type="bibr">51</xref>] were inconclusive, as this molecule showed off-target effects, inhibiting proliferation of Pin1-knockout as well as wild-type E&#x003bc;-<italic>myc</italic> tumors (data not shown). Our findings provide an ideal pre-clinical setting in which to characterize the activity and specificity of new Pin1-inhibitory compounds.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Mouse breeding, genotyping, and analysis</title><p>E&#x003bc;-<italic>myc</italic> transgenic mice [<xref rid="R24" ref-type="bibr">24</xref>] and <italic>Pin1</italic><sup>+/&#x02212;</sup> [<xref rid="R23" ref-type="bibr">23</xref>] mice were bred to obtain the various genotypic combinations described in this paper. Mice were maintained on a C57BL/6 background and genotyped as described [<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R35" ref-type="bibr">35</xref>]. Cohorts of E&#x003bc;-<italic>myc</italic> mice with <italic>Pin1<sup>+/+</sup></italic>, <italic>Pin1</italic><sup>+/&#x02212;</sup> or <italic>Pin1</italic><sup>&#x02212;/&#x02212;</sup> backgrounds were monitored twice a week for lymphoma development by peripheral lymph-node palpation. For pre-tumoral analysis, 6&#x02013;8 weeks old mice with no infiltration of peripheral lymph-nodes were used. Percentages and numbers of blood cell populations were measured using a Hematological analyzer (Beckman Coulter). For Tunel assay, purified B cells were fixed for 10 min in 2% formaldehyde, permeabilized in 0.1% triton in PBS, and analyzed with the ApopTag Plus fluorescein in situ Apoptosis detection kit (Millipore). Immuno-histochemical analysis was performed as described [<xref rid="R30" ref-type="bibr">30</xref>] with Monoclonal Rat Anti-Mouse Ki-67 Antigen Clone TEC-3 (DakoCytomation), and Polyclonal Rabbit Anti-Rat Immunoglobulins/HRP. The EnVision+ system (DakoCytomation) was used for signal detection. Immunoblot analysis was performed as described [<xref rid="R30" ref-type="bibr">30</xref>] with the following antibodies: rabbit polyclonal Myc N100 (custom-made antibody raised against the first 100 N-terminal aminoacids of c-Myc); anti c-Myc Y69 (abcam 32072); anti Ser 62-phosphorylated Myc (S62P-Myc) [<xref rid="R52" ref-type="bibr">52</xref>]; anti Thr 58-phosphorylated Myc (T58P-Myc) (Santa Cruz-135647); rabbit polyclonal anti-Pin1 [<xref rid="R11" ref-type="bibr">11</xref>]; anti-phospho-Histone H2A.X (Ser 139, 1:2000, Millipore); anti-p53 (1C12, 1:1000 Cell Signaling), anti-p53 (Ser15, 1:1000, Cell Signaling); anti-vinculin (Sigma). For preclinical studies, 10<sup>6</sup> cells derived from E&#x003bc;-<italic>Myc</italic> lymphomas were transplanted into syngeneic C57/Bl6 mice by tail vein injection. In order to induce the knockdown, recipient mice were fed with doxycycline-containing food either at the day of injection or when tumors became palpable. A control group of mice and some of the tumor-bearing mice were kept on standard doxycycline free diet. Mice were inspected 3 times a week for the insurgence of tumor masses.</p></sec><sec id="s4_2"><title>Construction of the conditional Pin1 shRNA vector</title><p>To generate shRNA targeting Pin1 (ShPin1), we cloned a 97-mer oligonucleotide (TGCTGTTGACAGTGAGCGCCACAGTATTTATTGTTCCTAATAGTGAAGC CACAGATGTATTAGGAACAATAAATACTGTGTTGC CTACTGCCTCGGA) designed by Dr. Johannes Zuber based on the massively parallel sensor based assay [<xref rid="R53" ref-type="bibr">53</xref>]. The 97mer served as a template for a PCR reaction performed using the using the primers miRE-Xho-fw (TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG) and miRE-EcoOligo-rev (TCTCGAATTCTAGCCCCTTGAAGTCCGAGGCAGTAGGC).</p><p>Primary E&#x003bc;-<italic>myc</italic> lymphomas were infected <italic>in vitro</italic> with viral supernatant containing either shPin1 or shRen and grown <italic>in vitro</italic> in tet-free medium. Cell growth was monitored using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). The shRNAs were induced <italic>in vitro</italic> by supplementing cells with 1 &#x003bc;g/mL doxycycline or <italic>in vivo</italic> with doxycycline-containing food.</p></sec><sec id="s4_3"><title>Flow cytometry and magnetic cell sorting of B-lymphocytes</title><p>For the analysis of B cell populations in pre-tumoral mice, bone marrow, splenic or white blood cells were incubated for 30 min with anti-CD45R/B220 PE, CD25-APC, B220-Cy7PE, c-kit-PE (BD Biosciences Pharmingen) and with fluorescein isothiocyanate (FITC)-conjugated anti-IgM (Jackson Immunoresearch). For cell cycle analysis, after surface staining, cells were fixed 10 min in 2% formaldehyde at RT, permeabilized with Cytofix/Cytoperm Kit (BD Biosciences Pharmingen) and incubated for 45 min with anti-Ki67/Alexa488 (BD Biosciences Pharmingen). Cells were fixed before of Hoechst staining. To measure ROS, cells were incubated with CellROX deep Red (Molecular Probes, C10422) and analyzed as described by the manufacturer. FlowFISH was performed using the Telomere PNA Kit/FITC for Flow Cytometry DAKO, as described by the manufacturer. Sample and control cells were washed in PBS, denaturated for 10 min at 80&#x000b0;C. Hybridization with Telomere PNA Probe/FITC was performed overnight. After two washing steps, cells were stained with PI in the dark at 2-8&#x000b0;C for 3 hours before of FACS acquisition. After flow cytometric analysis, the data obtained were used for the determination of the relative telomere length (RTL), calculated as the ratio between the telomere signal of each sample and that in the control 1301 cell line, with correction for the G0/G1 DNA index, as described by the manufacturer.</p><p>Splenic B cells for RNA and protein preparation were isolated as described [<xref rid="R35" ref-type="bibr">35</xref>]. For cell culture, we used the MACS B cell Isolation kit (Miltenyi Biotech). Purified B cells were plated in B cell medium (DMEM and IMDM in ratio 1:1, 10% fetal bovine serum, 1% glutamine, 1% penicillin/streptomycin and 25uM &#x00394;-mercaptoethanol) supplemented with 20 &#x003bc;g/ml LPS (Sigma L6529). Primary lymphomas were cultured in B cell medium, previously conditioned by irradiated (30Gy) NIH-3T3 cells. BrdU incorporation was analyzed as described [<xref rid="R30" ref-type="bibr">30</xref>]. MEFs derived from E12.5 embryos were infected with retroviruses encoding the MycER chimaera [<xref rid="R54" ref-type="bibr">54</xref>] and analyzed as previously described [<xref rid="R30" ref-type="bibr">30</xref>]. Cell death in MEFs cultures was assessed with the Caspase-Glo 3/7 kit (Promega), while cell growth was monitored using the CellTiter-Glo Luminescent Cell Viability Assay (Promega).</p></sec><sec id="s4_4"><title>RNA extraction and analysis</title><p>Total RNA purified using the Quiagen RNeasy Mini Kit was processed for RNA-seq, and the data analyzed as described [<xref rid="R40" ref-type="bibr">40</xref>]. The data are reported in <xref ref-type="supplementary-material" rid="SD2">Supplementary Table 1</xref>. Genes with a maximum expression value of RPKM &#x02265; 2 were hierarchically clustered with the R function &#x0201c;hclust&#x0201d; (Figure <xref ref-type="fig" rid="F4">4A</xref>). Differentially expressed genes (DEGs) were defined in the <italic>Pin1<sup>+/+</sup></italic> background as genes up- or down- regulated in pre-tumoral E&#x003bc;-<italic>myc</italic> relative to control B cells, with q-value &#x0003c; 0.05 and a maximum expression value of RPKM &#x02265; 2. For the identified DEGs the gene expression changes in pre-tumoral relative to control B cells (Figure <xref ref-type="fig" rid="F4">4B</xref>) was calculated as the ratio between the mean of RPKM values in Pre-tumoral B cells and the mean of RPKM values in control B cells. The log2 of the calculated values in Pin1+/+ (X-axes) and in Pin1&#x02212;/&#x02212; (Y-axes), were reported in the scatter-plot (Figure <xref ref-type="fig" rid="F4">4B</xref>). 100 ng of total RNA were processed for NanoString analysis as described by the manufacturer. The custom-made CodeSets used here as reported in <xref ref-type="supplementary-material" rid="SD2">Supplementary Tables 2-5</xref>, and the data in <xref ref-type="supplementary-material" rid="SD2">Supplementary Tables 6-9</xref>. Two of the CodeSets (<xref ref-type="supplementary-material" rid="SD2">Supplementary Tables 2, 4</xref>) were the same as those used in our previous work [<xref rid="R40" ref-type="bibr">40</xref>]. Dedicated nCounter software was used for data analysis, and raw counts were normalized to the internal positive control probes, included in each CodeSet, and to the housekeeping gene TBP. RNAseq data have been deposited and are accessible through GEO Series accession number GSE77482 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77482">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77482</ext-link>).</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY FIGURES AND TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-07-21786-s001.pdf" orientation="portrait" xlink:type="simple" id="d36e1820" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-07-21786-s002.xlsx" orientation="portrait" xlink:type="simple" id="d36e1822" position="anchor"/></supplementary-material></sec></body><back><ack><p>We thank Marcin Gorski for the design of NanoString CodeSets, Alberto Gobbi and Manuela Capillo for their help with the management of mouse colonies, Luca Zammattaro and Iros Barozzi for guidance with Bioinformatics and statistical analysis, Simona Ronzoni and Anna Sciullo for FACS analysis, Salvatore Bianchi for training on the NanoString platform, Dr. Johannes Zuber and Dr. Lars Zender for suggestions on shRNA epxreriments and Stefano Casola for comments on the manuscript.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The Authors declare no competing financial interests.</p></fn><fn fn-type="supported-by"><p><bold>GRANT SUPPORT</bold></p><p>This work was supported by grants from the EU-FP7 Program (EuroSyStem), the European Research Council, the Association for International Cancer Research (AICR), the Italian health ministry and the Italian Association for Cancer Research (AIRC) to B.A., the Italian Association for Cancer Research (AIRC, IG grant 13135) to S.C and by an AIRC Special Program &#x0201c;5 per mille&#x0201d; grant in Molecular and Clinical Oncology to GDS.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>KP</given-names></name><name><surname>Hanes</surname><given-names>SD</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><article-title>A human peptidyl-prolyl isomerase essential for regulation of mitosis</article-title><source>Nature</source><year>1996</year><volume>380</volume><fpage>544</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">8606777</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaffe</surname><given-names>MB</given-names></name><name><surname>Schutkowski</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>XZ</given-names></name><name><surname>Stukenberg</surname><given-names>PT</given-names></name><name><surname>Rahfeld</surname><given-names>JU</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kuang</surname><given-names>J</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name></person-group><article-title>Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism</article-title><source>Science</source><year>1997</year><volume>278</volume><fpage>1957</fpage><lpage>1960</lpage><pub-id pub-id-type="pmid">9395400</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranganathan</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Noel</surname><given-names>JP</given-names></name></person-group><article-title>Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent</article-title><source>Cell</source><year>1997</year><volume>89</volume><fpage>875</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">9200606</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>KP</given-names></name><name><surname>Zhou</surname><given-names>XZ</given-names></name></person-group><article-title>The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease</article-title><source>Nat Rev Mol Cell Biol</source><year>2007</year><volume>8</volume><fpage>904</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">17878917</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sears</surname><given-names>R</given-names></name><name><surname>Nuckolls</surname><given-names>F</given-names></name><name><surname>Haura</surname><given-names>E</given-names></name><name><surname>Taya</surname><given-names>Y</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><article-title>Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability</article-title><source>Genes Dev</source><year>2000</year><volume>14</volume><fpage>2501</fpage><lpage>2514</lpage><pub-id pub-id-type="pmid">11018017</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sears</surname><given-names>R</given-names></name><name><surname>Leone</surname><given-names>G</given-names></name><name><surname>DeGregori</surname><given-names>J</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><article-title>Ras enhances Myc protein stability</article-title><source>Mol Cell</source><year>1999</year><volume>3</volume><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">10078200</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>M</given-names></name><name><surname>Arnold</surname><given-names>H</given-names></name><name><surname>Chasse</surname><given-names>D</given-names></name><name><surname>Monteith</surname><given-names>T</given-names></name><name><surname>Ivaldi</surname><given-names>G</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Stukenberg</surname><given-names>PT</given-names></name><name><surname>Shenolikar</surname><given-names>S</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Counter</surname><given-names>CM</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name><name><surname>Means</surname><given-names>AR</given-names></name><etal/></person-group><article-title>A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells</article-title><source>Nat Cell Biol</source><year>2004</year><volume>6</volume><fpage>308</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">15048125</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>MA</given-names></name><name><surname>Hann</surname><given-names>SR</given-names></name></person-group><article-title>c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells</article-title><source>Mol Cell Biol</source><year>2000</year><volume>20</volume><fpage>2423</fpage><lpage>2435</lpage><pub-id pub-id-type="pmid">10713166</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Penn</surname><given-names>LZ</given-names></name></person-group><article-title>Reflecting on 25 years with MYC</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>976</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">19029958</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemann</surname><given-names>MT</given-names></name><name><surname>Bric</surname><given-names>A</given-names></name><name><surname>Teruya-Feldstein</surname><given-names>J</given-names></name><name><surname>Herbst</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>JA</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><article-title>Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants</article-title><source>Nature</source><year>2005</year><volume>436</volume><fpage>807</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">16094360</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zacchi</surname><given-names>P</given-names></name><name><surname>Gostissa</surname><given-names>M</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Salvagno</surname><given-names>C</given-names></name><name><surname>Avolio</surname><given-names>F</given-names></name><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Ronai</surname><given-names>Z</given-names></name><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Del Sal</surname><given-names>G</given-names></name></person-group><article-title>The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults</article-title><source>Nature</source><year>2002</year><volume>419</volume><fpage>853</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">12397362</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wulf</surname><given-names>GM</given-names></name><name><surname>Liou</surname><given-names>YC</given-names></name><name><surname>Ryo</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name></person-group><article-title>Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>47976</fpage><lpage>47979</lpage><pub-id pub-id-type="pmid">12388558</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorrentino</surname><given-names>G</given-names></name><name><surname>Mioni</surname><given-names>M</given-names></name><name><surname>Giorgi</surname><given-names>C</given-names></name><name><surname>Ruggeri</surname><given-names>N</given-names></name><name><surname>Pinton</surname><given-names>P</given-names></name><name><surname>Moll</surname><given-names>U</given-names></name><name><surname>Mantovani</surname><given-names>F</given-names></name><name><surname>Del Sal</surname><given-names>G</given-names></name></person-group><article-title>The prolyl-isomerase Pin1 activates the mitochondrial death program of p53</article-title><source>Cell Death Differ</source><year>2013</year><volume>20</volume><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">22935610</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grison</surname><given-names>A</given-names></name><name><surname>Mantovani</surname><given-names>F</given-names></name><name><surname>Comel</surname><given-names>A</given-names></name><name><surname>Agostoni</surname><given-names>E</given-names></name><name><surname>Gustincich</surname><given-names>S</given-names></name><name><surname>Persichetti</surname><given-names>F</given-names></name><name><surname>Del Sal</surname><given-names>G</given-names></name></person-group><article-title>Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>17979</fpage><lpage>17984</lpage><pub-id pub-id-type="pmid">22011578</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>F</given-names></name><name><surname>Zannini</surname><given-names>A</given-names></name><name><surname>Rustighi</surname><given-names>A</given-names></name><name><surname>Del Sal</surname><given-names>G</given-names></name></person-group><article-title>Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships</article-title><source>Biochim Biophys Acta</source><year>2015</year><volume>1850</volume><fpage>2048</fpage><lpage>2060</lpage><pub-id pub-id-type="pmid">25641576</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eischen</surname><given-names>CM</given-names></name><name><surname>Weber</surname><given-names>JD</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name></person-group><article-title>Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>2658</fpage><lpage>2669</lpage><pub-id pub-id-type="pmid">10541552</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Arevalo Lobo</surname><given-names>VJ</given-names></name><name><surname>Doni</surname><given-names>M</given-names></name><name><surname>Verrecchia</surname><given-names>A</given-names></name><name><surname>Sanulli</surname><given-names>S</given-names></name><name><surname>Faga</surname><given-names>G</given-names></name><name><surname>Piontini</surname><given-names>A</given-names></name><name><surname>Bianchi</surname><given-names>M</given-names></name><name><surname>Conacci-Sorrell</surname><given-names>M</given-names></name><name><surname>Mazzarol</surname><given-names>G</given-names></name><name><surname>Peg</surname><given-names>V</given-names></name><name><surname>Losa</surname><given-names>JH</given-names></name><name><surname>Ronchi</surname><given-names>P</given-names></name><name><surname>Ponzoni</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dual regulation of Myc by Abl</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>5261</fpage><lpage>5271</lpage><pub-id pub-id-type="pmid">23318434</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>AS</given-names></name><name><surname>Pelz</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Daniel</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Janghorban</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Morgan</surname><given-names>C</given-names></name><name><surname>Impey</surname><given-names>S</given-names></name><name><surname>Sears</surname><given-names>RC</given-names></name></person-group><article-title>Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis</article-title><source>Mol Cell Biol</source><year>2013</year><volume>33</volume><fpage>2930</fpage><lpage>2949</lpage><pub-id pub-id-type="pmid">23716601</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>SH</given-names></name><name><surname>Lau</surname><given-names>AW</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Inuzuka</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Shaik</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>DY</given-names></name><name><surname>Finn</surname><given-names>G</given-names></name><name><surname>Balastik</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Tron</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase</article-title><source>Mol Cell</source><year>2012</year><volume>46</volume><fpage>771</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">22608923</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welcker</surname><given-names>M</given-names></name><name><surname>Orian</surname><given-names>A</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Grim</surname><given-names>JE</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Eisenman</surname><given-names>RN</given-names></name><name><surname>Clurman</surname><given-names>BE</given-names></name></person-group><article-title>The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>9085</fpage><lpage>9090</lpage><pub-id pub-id-type="pmid">15150404</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yada</surname><given-names>M</given-names></name><name><surname>Hatakeyama</surname><given-names>S</given-names></name><name><surname>Kamura</surname><given-names>T</given-names></name><name><surname>Nishiyama</surname><given-names>M</given-names></name><name><surname>Tsunematsu</surname><given-names>R</given-names></name><name><surname>Imaki</surname><given-names>H</given-names></name><name><surname>Ishida</surname><given-names>N</given-names></name><name><surname>Okumura</surname><given-names>F</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>KI</given-names></name></person-group><article-title>Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>2116</fpage><lpage>2125</lpage><pub-id pub-id-type="pmid">15103331</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimori</surname><given-names>F</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Uchida</surname><given-names>C</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name></person-group><article-title>Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>265</volume><fpage>658</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">10600477</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atchison</surname><given-names>FW</given-names></name><name><surname>Capel</surname><given-names>B</given-names></name><name><surname>Means</surname><given-names>AR</given-names></name></person-group><article-title>Pin1 regulates the timing of mammalian primordial germ cell proliferation</article-title><source>Development</source><year>2003</year><volume>130</volume><fpage>3579</fpage><lpage>3586</lpage><pub-id pub-id-type="pmid">12810604</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JM</given-names></name><name><surname>Harris</surname><given-names>AW</given-names></name><name><surname>Pinkert</surname><given-names>CA</given-names></name><name><surname>Corcoran</surname><given-names>LM</given-names></name><name><surname>Alexander</surname><given-names>WS</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name><name><surname>Brinster</surname><given-names>RL</given-names></name></person-group><article-title>The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice</article-title><source>Nature</source><year>1985</year><volume>318</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">3906410</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langdon</surname><given-names>WY</given-names></name><name><surname>Harris</surname><given-names>AW</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>JM</given-names></name></person-group><article-title>The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice</article-title><source>Cell</source><year>1986</year><volume>47</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">3093082</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaux</surname><given-names>DL</given-names></name><name><surname>Adams</surname><given-names>JM</given-names></name><name><surname>Alexander</surname><given-names>WS</given-names></name><name><surname>Pike</surname><given-names>BL</given-names></name></person-group><article-title>Immunologic competence of B cells subjected to constitutive c-myc oncogene expression in immunoglobulin heavy chain enhancer myc transgenic mice</article-title><source>J Immunol</source><year>1987</year><volume>139</volume><fpage>3854</fpage><lpage>3860</lpage><pub-id pub-id-type="pmid">2445821</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zindy</surname><given-names>F</given-names></name><name><surname>Eischen</surname><given-names>CM</given-names></name><name><surname>Randle</surname><given-names>DH</given-names></name><name><surname>Kamijo</surname><given-names>T</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name></person-group><article-title>Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization</article-title><source>Genes Dev</source><year>1998</year><volume>12</volume><fpage>2424</fpage><lpage>2433</lpage><pub-id pub-id-type="pmid">9694806</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eilers</surname><given-names>M</given-names></name><name><surname>Schirm</surname><given-names>S</given-names></name><name><surname>Bishop</surname><given-names>JM</given-names></name></person-group><article-title>The MYC protein activates transcription of the alpha-prothymosin gene</article-title><source>EMBO J</source><year>1991</year><volume>10</volume><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">1989881</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perna</surname><given-names>D</given-names></name><name><surname>Faga</surname><given-names>G</given-names></name><name><surname>Verrecchia</surname><given-names>A</given-names></name><name><surname>Gorski</surname><given-names>MM</given-names></name><name><surname>Barozzi</surname><given-names>I</given-names></name><name><surname>Narang</surname><given-names>V</given-names></name><name><surname>Khng</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>KC</given-names></name><name><surname>Sung</surname><given-names>WK</given-names></name><name><surname>Sanges</surname><given-names>R</given-names></name><name><surname>Stupka</surname><given-names>E</given-names></name><name><surname>Oskarsson</surname><given-names>T</given-names></name><name><surname>Trumpp</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>1695</fpage><lpage>1709</lpage><pub-id pub-id-type="pmid">21860422</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campaner</surname><given-names>S</given-names></name><name><surname>Doni</surname><given-names>M</given-names></name><name><surname>Hydbring</surname><given-names>P</given-names></name><name><surname>Verrecchia</surname><given-names>A</given-names></name><name><surname>Bianchi</surname><given-names>L</given-names></name><name><surname>Sardella</surname><given-names>D</given-names></name><name><surname>Schleker</surname><given-names>T</given-names></name><name><surname>Perna</surname><given-names>D</given-names></name><name><surname>Tronnersjo</surname><given-names>S</given-names></name><name><surname>Murga</surname><given-names>M</given-names></name><name><surname>Fernandez-Capetillo</surname><given-names>O</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name><name><surname>Larsson</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Cdk2 suppresses cellular senescence induced by the c-myc oncogene</article-title><source>Nat Cell Biol</source><year>2010</year><volume>12</volume><fpage>54</fpage><lpage>59</lpage><comment>sup pp 51-14</comment><pub-id pub-id-type="pmid">20010815</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryo</surname><given-names>A</given-names></name><name><surname>Liou</surname><given-names>YC</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name><name><surname>Wulf</surname><given-names>G</given-names></name></person-group><article-title>Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer</article-title><source>J Cell Sci</source><year>2003</year><volume>116</volume><fpage>773</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">12571275</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz-Espin</surname><given-names>D</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name></person-group><article-title>Cellular senescence: from physiology to pathology</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><fpage>482</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">24954210</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vafa</surname><given-names>O</given-names></name><name><surname>Wade</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>S</given-names></name><name><surname>Beeche</surname><given-names>M</given-names></name><name><surname>Pandita</surname><given-names>TK</given-names></name><name><surname>Hampton</surname><given-names>GM</given-names></name><name><surname>Wahl</surname><given-names>GM</given-names></name></person-group><article-title>c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability</article-title><source>Mol Cell</source><year>2002</year><volume>9</volume><fpage>1031</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">12049739</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reimann</surname><given-names>M</given-names></name><name><surname>Loddenkemper</surname><given-names>C</given-names></name><name><surname>Rudolph</surname><given-names>C</given-names></name><name><surname>Schildhauer</surname><given-names>I</given-names></name><name><surname>Teichmann</surname><given-names>B</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Schlegelberger</surname><given-names>B</given-names></name><name><surname>Dorken</surname><given-names>B</given-names></name><name><surname>Schmitt</surname><given-names>CA</given-names></name></person-group><article-title>The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>2996</fpage><lpage>3004</lpage><pub-id pub-id-type="pmid">17562874</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorrini</surname><given-names>C</given-names></name><name><surname>Squatrito</surname><given-names>M</given-names></name><name><surname>Luise</surname><given-names>C</given-names></name><name><surname>Syed</surname><given-names>N</given-names></name><name><surname>Perna</surname><given-names>D</given-names></name><name><surname>Wark</surname><given-names>L</given-names></name><name><surname>Martinato</surname><given-names>F</given-names></name><name><surname>Sardella</surname><given-names>D</given-names></name><name><surname>Verrecchia</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>S</given-names></name><name><surname>Confalonieri</surname><given-names>S</given-names></name><name><surname>Cesaroni</surname><given-names>M</given-names></name><name><surname>Marchesi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response</article-title><source>Nature</source><year>2007</year><volume>448</volume><fpage>1063</fpage><lpage>1067</lpage><pub-id pub-id-type="pmid">17728759</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campisi</surname><given-names>J</given-names></name><name><surname>d'Adda di Fagagna</surname><given-names>F</given-names></name></person-group><article-title>Cellular senescence: when bad things happen to good cells</article-title><source>Nat Rev Mol Cell Biol</source><year>2007</year><volume>8</volume><fpage>729</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">17667954</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Tun-Kyi</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Soohoo</surname><given-names>C</given-names></name><name><surname>Finn</surname><given-names>G</given-names></name><name><surname>Balastik</surname><given-names>M</given-names></name><name><surname>Pastorino</surname><given-names>L</given-names></name><name><surname>Wulf</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>XZ</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name></person-group><article-title>Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance</article-title><source>Nat Cell Biol</source><year>2009</year><volume>11</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">19060891</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>DJ</given-names></name><name><surname>Junttila</surname><given-names>MR</given-names></name><name><surname>Pouyet</surname><given-names>L</given-names></name><name><surname>Karnezis</surname><given-names>A</given-names></name><name><surname>Shchors</surname><given-names>K</given-names></name><name><surname>Bui</surname><given-names>DA</given-names></name><name><surname>Brown-Swigart</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>L</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><article-title>Distinct thresholds govern Myc's biological output in vivo</article-title><source>Cancer Cell</source><year>2008</year><volume>14</volume><fpage>447</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">19061836</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sears</surname><given-names>RC</given-names></name></person-group><article-title>The life cycle of C-myc: from synthesis to degradation</article-title><source>Cell Cycle</source><year>2004</year><volume>3</volume><fpage>1133</fpage><lpage>1137</lpage><pub-id pub-id-type="pmid">15467447</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabo</surname><given-names>A</given-names></name><name><surname>Kress</surname><given-names>TR</given-names></name><name><surname>Pelizzola</surname><given-names>M</given-names></name><name><surname>de Pretis</surname><given-names>S</given-names></name><name><surname>Gorski</surname><given-names>MM</given-names></name><name><surname>Tesi</surname><given-names>A</given-names></name><name><surname>Morelli</surname><given-names>MJ</given-names></name><name><surname>Bora</surname><given-names>P</given-names></name><name><surname>Doni</surname><given-names>M</given-names></name><name><surname>Verrecchia</surname><given-names>A</given-names></name><name><surname>Tonelli</surname><given-names>C</given-names></name><name><surname>Faga</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis</article-title><source>Nature</source><year>2014</year><volume>511</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">25043028</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>SR</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Fernandez</surname><given-names>P</given-names></name><name><surname>Taubert</surname><given-names>S</given-names></name><name><surname>Amati</surname><given-names>B</given-names></name></person-group><article-title>Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation</article-title><source>Genes Dev</source><year>2001</year><volume>15</volume><fpage>2069</fpage><lpage>2082</lpage><pub-id pub-id-type="pmid">11511539</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>CA</given-names></name><name><surname>McCurrach</surname><given-names>ME</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Wallace-Brodeur</surname><given-names>RR</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><article-title>INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>2670</fpage><lpage>2677</lpage><pub-id pub-id-type="pmid">10541553</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>CP</given-names></name><name><surname>Brown-Swigart</surname><given-names>L</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><article-title>Modeling the therapeutic efficacy of p53 restoration in tumors</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>1323</fpage><lpage>1334</lpage><pub-id pub-id-type="pmid">17182091</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wulf</surname><given-names>G</given-names></name><name><surname>Garg</surname><given-names>P</given-names></name><name><surname>Liou</surname><given-names>YC</given-names></name><name><surname>Iglehart</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name></person-group><article-title>Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>3397</fpage><lpage>3407</lpage><pub-id pub-id-type="pmid">15257284</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wulf</surname><given-names>GM</given-names></name><name><surname>Ryo</surname><given-names>A</given-names></name><name><surname>Wulf</surname><given-names>GG</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Petkova</surname><given-names>V</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name></person-group><article-title>Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>3459</fpage><lpage>3472</lpage><pub-id pub-id-type="pmid">11432833</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Kimzey</surname><given-names>A</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Sowadski</surname><given-names>JM</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name><name><surname>Wang</surname><given-names>DG</given-names></name></person-group><article-title>Prevalent overexpression of prolyl isomerase Pin1 in human cancers</article-title><source>Am J Pathol</source><year>2004</year><volume>164</volume><fpage>1727</fpage><lpage>1737</lpage><pub-id pub-id-type="pmid">15111319</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>AS</given-names></name><name><surname>Sears</surname><given-names>RC</given-names></name></person-group><article-title>MYC degradation</article-title><source>Cold Spring Harb Perspect Med</source><year>2014</year><fpage>4</fpage></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reimann</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Loddenkemper</surname><given-names>C</given-names></name><name><surname>Dorr</surname><given-names>JR</given-names></name><name><surname>Tabor</surname><given-names>V</given-names></name><name><surname>Aichele</surname><given-names>P</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Dorken</surname><given-names>B</given-names></name><name><surname>Jenuwein</surname><given-names>T</given-names></name><name><surname>Schmitt</surname><given-names>CA</given-names></name></person-group><article-title>Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence</article-title><source>Cancer Cell</source><year>2010</year><volume>17</volume><fpage>262</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">20227040</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Riggelen</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>J</given-names></name><name><surname>Otto</surname><given-names>T</given-names></name><name><surname>Beuger</surname><given-names>V</given-names></name><name><surname>Yetil</surname><given-names>A</given-names></name><name><surname>Choi</surname><given-names>PS</given-names></name><name><surname>Kosan</surname><given-names>C</given-names></name><name><surname>Moroy</surname><given-names>T</given-names></name><name><surname>Felsher</surname><given-names>DW</given-names></name><name><surname>Eilers</surname><given-names>M</given-names></name></person-group><article-title>The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance</article-title><source>Genes Dev</source><year>2010</year><volume>24</volume><fpage>1281</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">20551174</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kress</surname><given-names>TR</given-names></name><name><surname>Sabo</surname><given-names>A</given-names></name><name><surname>Amati</surname><given-names>B</given-names></name></person-group><article-title>MYC: connecting selective transcriptional control to global RNA production</article-title><source>Nat Rev Cancer</source><year>2015</year><volume>15</volume><fpage>593</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">26383138</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatara</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Bamba</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name></person-group><article-title>Dipentamethylene thiuram monosulfide is a novel inhibitor of Pin1</article-title><source>Biochem Biophys Res Commun</source><year>2009</year><volume>384</volume><fpage>394</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">19422802</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campaner</surname><given-names>S</given-names></name><name><surname>Doni</surname><given-names>M</given-names></name><name><surname>Verrecchia</surname><given-names>A</given-names></name><name><surname>Faga</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>L</given-names></name><name><surname>Amati</surname><given-names>B</given-names></name></person-group><article-title>Myc, Cdk2 and cellular senescence: Old players, new game</article-title><source>Cell Cycle</source><year>2010</year><volume>9</volume><fpage>3655</fpage><lpage>3661</lpage><pub-id pub-id-type="pmid">20818171</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellmann</surname><given-names>C</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>McJunkin</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Malone</surname><given-names>CD</given-names></name><name><surname>Dickins</surname><given-names>RA</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Hengartner</surname><given-names>MO</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><article-title>Functional identification of optimized RNAi triggers using a massively parallel sensor assay</article-title><source>Mol Cell</source><year>2011</year><volume>41</volume><fpage>733</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">21353615</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littlewood</surname><given-names>TD</given-names></name><name><surname>Hancock</surname><given-names>DC</given-names></name><name><surname>Danielian</surname><given-names>PS</given-names></name><name><surname>Parker</surname><given-names>MG</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><article-title>A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins</article-title><source>Nucleic Acids Res</source><year>1995</year><volume>23</volume><fpage>1686</fpage><lpage>1690</lpage><pub-id pub-id-type="pmid">7784172</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>RR</given-names></name><name><surname>Hayakawa</surname><given-names>K</given-names></name></person-group><article-title>B cell development pathways</article-title><source>Annu Rev Immunol</source><year>2001</year><volume>19</volume><fpage>595</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">11244048</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Dubois</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><article-title>Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells</article-title><source>Mol Cell</source><year>2012</year><volume>46</volume><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">22387025</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauzon</surname><given-names>W</given-names></name><name><surname>Sanchez Dardon</surname><given-names>J</given-names></name><name><surname>Cameron</surname><given-names>DW</given-names></name><name><surname>Badley</surname><given-names>AD</given-names></name></person-group><article-title>Flow cytometric measurement of telomere length</article-title><source>Cytometry</source><year>2000</year><volume>42</volume><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">10861688</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellmann</surname><given-names>C</given-names></name><name><surname>Hoffmann</surname><given-names>T</given-names></name><name><surname>Sridhar</surname><given-names>V</given-names></name><name><surname>Hopfgartner</surname><given-names>B</given-names></name><name><surname>Muhar</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>DY</given-names></name><name><surname>Barbosa</surname><given-names>IA</given-names></name><name><surname>Kwon</surname><given-names>JS</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Sinha</surname><given-names>N</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name></person-group><article-title>An optimized microRNA backbone for effective single-copy RNAi</article-title><source>Cell Rep</source><year>2013</year><volume>5</volume><fpage>1704</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">24332856</pub-id></element-citation></ref></ref-list></back></article>